EA201790565A1 - Композиции и способы для лечения предраковых поражений кожи - Google Patents

Композиции и способы для лечения предраковых поражений кожи

Info

Publication number
EA201790565A1
EA201790565A1 EA201790565A EA201790565A EA201790565A1 EA 201790565 A1 EA201790565 A1 EA 201790565A1 EA 201790565 A EA201790565 A EA 201790565A EA 201790565 A EA201790565 A EA 201790565A EA 201790565 A1 EA201790565 A1 EA 201790565A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
lesions
predicative
skin
Prior art date
Application number
EA201790565A
Other languages
English (en)
Other versions
EA036833B1 (ru
Inventor
Линн Корнелиус
Шадмехр Демехри
Рафаэль Копан
Original Assignee
Вашингтон Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вашингтон Юниверсити filed Critical Вашингтон Юниверсити
Publication of EA201790565A1 publication Critical patent/EA201790565A1/ru
Publication of EA036833B1 publication Critical patent/EA036833B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение охватывает композиции и способы лечения предраковых поражений кожи. Композиции по изобретению содержат цитотоксический агент и индуктор тимусного стромального лимфопоэтина (ТСЛП).
EA201790565A 2014-09-10 2015-09-10 Способ лечения предраковых поражений кожи EA036833B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048586P 2014-09-10 2014-09-10
PCT/US2015/049434 WO2016040638A2 (en) 2014-09-10 2015-09-10 Compositions and methods for treatment of pre-cancerous skin lesions

Publications (2)

Publication Number Publication Date
EA201790565A1 true EA201790565A1 (ru) 2017-08-31
EA036833B1 EA036833B1 (ru) 2020-12-24

Family

ID=55459695

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790565A EA036833B1 (ru) 2014-09-10 2015-09-10 Способ лечения предраковых поражений кожи

Country Status (16)

Country Link
US (3) US10905763B2 (ru)
EP (2) EP3939593A1 (ru)
KR (1) KR102573972B1 (ru)
CN (1) CN107073017A (ru)
AU (3) AU2015315047A1 (ru)
BR (1) BR112017004893A2 (ru)
CA (1) CA2963922C (ru)
CL (1) CL2017000605A1 (ru)
DK (1) DK3191103T3 (ru)
EA (1) EA036833B1 (ru)
ES (1) ES2891305T3 (ru)
IL (1) IL251089A0 (ru)
MX (1) MX2017003262A (ru)
PH (1) PH12017500677A1 (ru)
UA (1) UA121222C2 (ru)
WO (1) WO2016040638A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939593A1 (en) 2014-09-10 2022-01-19 Washington University Compositions and methods for treatment of pre-cancerous skin lesions
AU2018216043B2 (en) * 2017-02-06 2020-02-27 3Skin As Sunscreen composition
WO2019094500A1 (en) * 2017-11-09 2019-05-16 David Glazer Scott Compositions and methods for the treatment of skin lesions
CN112654368B (zh) * 2018-07-05 2024-03-26 总医院公司 用于局部递送药剂以治疗癌症的组合物和方法
MX2021014028A (es) * 2019-05-17 2022-02-21 Univ Pennsylvania Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
KR102321027B1 (ko) 2019-06-14 2021-11-03 이준성 전선관 커넥터
KR102316303B1 (ko) 2019-06-17 2021-10-22 이준성 전선 연결용 커버판
WO2021099901A1 (en) * 2019-11-19 2021-05-27 Intas Pharmaceuticals Ltd. Stable topical pharmaceutical composition
DK202370132A1 (en) * 2023-03-14 2024-10-10 Repoceuticals Aps Compositions for use in the treatment of actinic keratosis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4925661A (en) 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4755388A (en) 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
DE3542773A1 (de) 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US4820711A (en) * 1987-05-15 1989-04-11 Pearlman Dale L Method for treating actinic keratosis with cytotoxic agents
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
IL140005A0 (en) * 1998-06-26 2002-02-10 Aventis Pharm Prod Inc Method of treatment for dermatological disorders and compositions therefor
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
WO2005059509A2 (en) 2003-12-12 2005-06-30 Saint Louis University Biosensors for detecting macromolecules and other analytes
AU2005226649B2 (en) 2004-03-22 2010-04-29 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US9173835B2 (en) * 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
AU2009335943A1 (en) * 2008-12-19 2013-10-24 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
WO2012074842A2 (en) * 2010-11-23 2012-06-07 The United States Of America, As Represented By The Secretary, National Institute Of Health Compositions and methods for treating neoplasia
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
EP3939593A1 (en) 2014-09-10 2022-01-19 Washington University Compositions and methods for treatment of pre-cancerous skin lesions

Also Published As

Publication number Publication date
KR20170058961A (ko) 2017-05-29
AU2023200052A1 (en) 2023-02-09
AU2020281015A1 (en) 2021-01-07
EP3191103A4 (en) 2018-05-16
CA2963922C (en) 2023-06-27
DK3191103T3 (da) 2021-09-27
AU2020281015B2 (en) 2022-10-06
PH12017500677A1 (en) 2017-10-09
IL251089A0 (en) 2017-04-30
ES2891305T3 (es) 2022-01-27
US20230026855A1 (en) 2023-01-26
AU2015315047A1 (en) 2017-04-27
US10905763B2 (en) 2021-02-02
US20210128732A1 (en) 2021-05-06
WO2016040638A3 (en) 2016-09-01
EP3191103B1 (en) 2021-09-01
UA121222C2 (uk) 2020-04-27
CA2963922A1 (en) 2016-03-17
US11478549B2 (en) 2022-10-25
US20170246299A1 (en) 2017-08-31
MX2017003262A (es) 2017-12-04
WO2016040638A2 (en) 2016-03-17
EA036833B1 (ru) 2020-12-24
AU2020281015C1 (en) 2023-01-19
EP3939593A1 (en) 2022-01-19
CL2017000605A1 (es) 2017-11-10
EP3191103A2 (en) 2017-07-19
BR112017004893A2 (pt) 2017-12-12
KR102573972B1 (ko) 2023-09-01
CN107073017A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201691582A1 (ru) Новые фармацевтические препараты
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201790413A1 (ru) Антитела против tigit
EA201691974A1 (ru) Антитела против ox40 и способы их применения
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2017006694A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
GB2541571A (en) Pharmaceutical compositions
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201791095A1 (ru) Способ лечения рака
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM